{"title":"新型人工智能系统在结肠镜检查中检测腺瘤:系统回顾和网络荟萃分析。","authors":"Sunny Kumar, Mahveer Maheshwari, Shahnoor Aleem, Zoha Batool, Nawal Alsubaie, Saifullah Syed, Nida Fatima Daterdiwala, Hina Fatima Memon, Jaweria Azeem, Sajida Moiz Hussain Qamari, Mohammad Jawwad","doi":"10.14309/ctg.0000000000000904","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Artificial intelligence (AI) has the potential to improve adenoma detection rates (ADRs) during colonoscopy, but the efficacy of various AI-assisted systems remains unclear. To evaluate and compare the effectiveness of different AI-assisted systems for detecting colorectal neoplasia during colonoscopy.</p><p><strong>Methods: </strong>A systematic literature search of PubMed, Scopus, and Google Scholar databases was conducted up to March 4, 2025, to identify randomized controlled trials comparing AI-assisted colonoscopy with conventional colonoscopy. The analysis included AI systems such as GI Genius (Medtronic, Dublin, Ireland), CAD EYE (Fujifilm, Tokyo, Japan), ENDOANGEL, EndoScreener, and EndoAID. The primary outcome was ADR, analyzed using random-effects models to calculate pooled odds ratios (OR) and 95% confidence intervals (CI). Surface under the cumulative ranking curve (SUCRA) rankings and subgroup analyses were also performed.</p><p><strong>Results: </strong>Seventeen randomized controlled trials with 10,547 participants were included. ENDOANGEL showed the highest efficacy (OR 1.84, 95% CI 1.50-2.30; SUCRA 0.9), followed by EndoAID (OR 1.64, 95% CI 1.20-2.26; SUCRA 0.7). CAD EYE and GI Genius were similarly ranked (OR 1.46 and 1.45, respectively). EndoScreener was ranked just above the control group (OR 1.37, 95% CI 1.20-1.56; SUCRA 0.4).</p><p><strong>Discussion: </strong>AI-assisted colonoscopy systems showed improved ADR detection rates compared with traditional colonoscopy. These results suggest that artificial intelligence may help enhance detection during colonoscopy procedures; however, additional large-scale studies are needed to confirm these findings.</p>","PeriodicalId":10278,"journal":{"name":"Clinical and Translational Gastroenterology","volume":" ","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Novel Artificial Intelligence Systems in Detecting Adenomas in Colonoscopy: A Systemic Review and Network Meta-Analysis.\",\"authors\":\"Sunny Kumar, Mahveer Maheshwari, Shahnoor Aleem, Zoha Batool, Nawal Alsubaie, Saifullah Syed, Nida Fatima Daterdiwala, Hina Fatima Memon, Jaweria Azeem, Sajida Moiz Hussain Qamari, Mohammad Jawwad\",\"doi\":\"10.14309/ctg.0000000000000904\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Artificial intelligence (AI) has the potential to improve adenoma detection rates (ADRs) during colonoscopy, but the efficacy of various AI-assisted systems remains unclear. To evaluate and compare the effectiveness of different AI-assisted systems for detecting colorectal neoplasia during colonoscopy.</p><p><strong>Methods: </strong>A systematic literature search of PubMed, Scopus, and Google Scholar databases was conducted up to March 4, 2025, to identify randomized controlled trials comparing AI-assisted colonoscopy with conventional colonoscopy. The analysis included AI systems such as GI Genius (Medtronic, Dublin, Ireland), CAD EYE (Fujifilm, Tokyo, Japan), ENDOANGEL, EndoScreener, and EndoAID. The primary outcome was ADR, analyzed using random-effects models to calculate pooled odds ratios (OR) and 95% confidence intervals (CI). Surface under the cumulative ranking curve (SUCRA) rankings and subgroup analyses were also performed.</p><p><strong>Results: </strong>Seventeen randomized controlled trials with 10,547 participants were included. ENDOANGEL showed the highest efficacy (OR 1.84, 95% CI 1.50-2.30; SUCRA 0.9), followed by EndoAID (OR 1.64, 95% CI 1.20-2.26; SUCRA 0.7). CAD EYE and GI Genius were similarly ranked (OR 1.46 and 1.45, respectively). EndoScreener was ranked just above the control group (OR 1.37, 95% CI 1.20-1.56; SUCRA 0.4).</p><p><strong>Discussion: </strong>AI-assisted colonoscopy systems showed improved ADR detection rates compared with traditional colonoscopy. These results suggest that artificial intelligence may help enhance detection during colonoscopy procedures; however, additional large-scale studies are needed to confirm these findings.</p>\",\"PeriodicalId\":10278,\"journal\":{\"name\":\"Clinical and Translational Gastroenterology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2025-08-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical and Translational Gastroenterology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.14309/ctg.0000000000000904\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Translational Gastroenterology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.14309/ctg.0000000000000904","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景:人工智能(AI)有可能提高结肠镜检查时的腺瘤检出率(adr),但各种人工智能辅助系统的疗效尚不清楚。目的:评价和比较不同人工智能辅助系统在结肠镜检查中检测结直肠肿瘤的有效性。设计:系统检索PubMed、Scopus和谷歌Scholar数据库,检索截至2025年3月4日的随机对照试验(rct),比较人工智能辅助结肠镜检查和传统结肠镜检查。分析包括GI-Genius(美敦力)、CAD-EYE(富士胶片)、Endoangel、Endoscreener和EndoAID等人工智能系统。主要终点是腺瘤检出率(ADR),使用随机效应模型计算合并优势比(OR)和95%置信区间(CI)。还进行了SUCRA排名和亚组分析。结果:纳入17项随机对照试验,共10,547名受试者。EndoAngel的疗效最高(OR为1.84,95% CI 1.50-2.30; SUCRA为0.9),其次是EndoAID (OR为1.64,95% CI 1.20-2.26; SUCRA为0.7)。CAD-EYE和GI-Genius的排名相似(OR分别为1.46和1.45)。Endoscreener的评分刚好高于对照组(OR 1.37, 95% CI 1.20-1.56; SUCRA 0.4)。结论:人工智能辅助结肠镜系统与传统结肠镜相比,ADR检出率更高。这些结果表明,人工智能可能有助于增强结肠镜检查过程中的检测;然而,需要更多的大规模研究来证实这些发现。
Novel Artificial Intelligence Systems in Detecting Adenomas in Colonoscopy: A Systemic Review and Network Meta-Analysis.
Introduction: Artificial intelligence (AI) has the potential to improve adenoma detection rates (ADRs) during colonoscopy, but the efficacy of various AI-assisted systems remains unclear. To evaluate and compare the effectiveness of different AI-assisted systems for detecting colorectal neoplasia during colonoscopy.
Methods: A systematic literature search of PubMed, Scopus, and Google Scholar databases was conducted up to March 4, 2025, to identify randomized controlled trials comparing AI-assisted colonoscopy with conventional colonoscopy. The analysis included AI systems such as GI Genius (Medtronic, Dublin, Ireland), CAD EYE (Fujifilm, Tokyo, Japan), ENDOANGEL, EndoScreener, and EndoAID. The primary outcome was ADR, analyzed using random-effects models to calculate pooled odds ratios (OR) and 95% confidence intervals (CI). Surface under the cumulative ranking curve (SUCRA) rankings and subgroup analyses were also performed.
Results: Seventeen randomized controlled trials with 10,547 participants were included. ENDOANGEL showed the highest efficacy (OR 1.84, 95% CI 1.50-2.30; SUCRA 0.9), followed by EndoAID (OR 1.64, 95% CI 1.20-2.26; SUCRA 0.7). CAD EYE and GI Genius were similarly ranked (OR 1.46 and 1.45, respectively). EndoScreener was ranked just above the control group (OR 1.37, 95% CI 1.20-1.56; SUCRA 0.4).
Discussion: AI-assisted colonoscopy systems showed improved ADR detection rates compared with traditional colonoscopy. These results suggest that artificial intelligence may help enhance detection during colonoscopy procedures; however, additional large-scale studies are needed to confirm these findings.
期刊介绍:
Clinical and Translational Gastroenterology (CTG), published on behalf of the American College of Gastroenterology (ACG), is a peer-reviewed open access online journal dedicated to innovative clinical work in the field of gastroenterology and hepatology. CTG hopes to fulfill an unmet need for clinicians and scientists by welcoming novel cohort studies, early-phase clinical trials, qualitative and quantitative epidemiologic research, hypothesis-generating research, studies of novel mechanisms and methodologies including public health interventions, and integration of approaches across organs and disciplines. CTG also welcomes hypothesis-generating small studies, methods papers, and translational research with clear applications to human physiology or disease.
Colon and small bowel
Endoscopy and novel diagnostics
Esophagus
Functional GI disorders
Immunology of the GI tract
Microbiology of the GI tract
Inflammatory bowel disease
Pancreas and biliary tract
Liver
Pathology
Pediatrics
Preventative medicine
Nutrition/obesity
Stomach.